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INTRODUCTION 
  
 Diabetes Mellitus is one of the leading cause of 
morbidity and mortality worldwide. Its Prevalence is 
gearing up at a faster pace all over the world especially in 
developing countries like India 
 
           It is the most important risk factor in the 
pathogenesis of Acute Coronary syndrome. Coronary artery 
disease is one of the most common Macro vascular  
complications of Diabetes, especially Type 2 diabetes. It is 
the leading cause of mortality and morbidity in diabetes.  
 
           In addition, diabetic patients are likely to have Poor 
treatment outcome compared with non-Diabetic controls. Its 
occurrence is increasing in younger age group,causing 
premature coronary artery disease and premature death 
inflicting economic burden to the family and to the society.  
 
 Recently studies are focussing on serum Fibrinogen 
and its role in the pathogenesis of Coronary artery disease 
in Diabetes. Fibrinogen being an acute phase reactant is 
 2 
also a pro-coagulant. It plays a major role in coagulation of 
blood. It has a significant role in Athero-thrombosis. Hence 
its role in adverse cardiac events in Diabetics and its 
prognostic value is currently the study of interest.  
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AIMS & OBJECTIVES 
 
 To determine the concentration of Fibrinogen in 
diabetic CAD and its causal relationship to adverse 
cardiac events. 
 
 To ascertain serum fibrinogen‟spredictive value of 
major adverse cardiac events in Diabetic CAD.  
 
 To ascertain the prognostic value of serum fibrinogen 
in Diabetic patients presenting with subsequent major 
adverse cardiac events.  
 
 To evaluate the relation between serum Fibrinogen 
and other factors that cause adverse cardiac events.  
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REVIEW OF LITERATURE 
 
DIABETES MELLITUS 
 It is a metabolic disorder of varied aetiology 
characterised by chronic hyperglycaemia and altered 
metabolism of carbohydrates, protein and fat leading to 
vascular syndrome affecting small and large sized blood 
vessels. It results from  
 Defective insulin secretion 
 Defective insulin action         or  
 Both 
 
EPIDEMIOLOGY 
 The prevalence of diabetes is increasing worldwide 
and in particular, developing countries like India. It has 
now become an important public health problem in India. 
With this pace, the Diabetic population in India would be 
around 70 million by 2030.At present, India heads the list 
of countries with highest population of Diabetics. The 
prevalence of DM is progressively stepping up and in 
particular T2DM prevalence is stepping up with rapid phase 
due to following factors  
 5 
 Social habits leading to obesity 
 Idle nature of daily routine activities  
 Industrialisation 
 Ageing of people 
 Geographic status 
 Genetic factors 
 Environmental factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
CLASSIFICATION
1
: 
 
 7 
 
 
 
 8 
 Inspite of ongoing research and advent of newer 
Antidiabeticdrugs , Diabetes  is still considered high risk , 
causing high occurrence of Coronary artery disease and 
cerebrovascular accidents. 
2,3 ,4
 
               
 Incidence of microvascular complication such as 
Retinopathy, neuropathy and Nephropathy are also much 
higher in Diabetes.
5,6 ,7
 
 
TYPE I DIABETES: 
 Various genetic factors, environmental and 
immunological components contribute to its development 
causing ultimately, pancreatic beta cell damage and 
absolute insulin deficiency as a result.  
 
          The immune mechanism that underlies the 
development of T1DM is auto immunity mediated by T – 
cell, where autoantibodies attacks beta cells of pancreatic 
islets and destroys them. 
 
 In most individual there is autoimmune destruction of 
beta cells and may have evidence to it, in form of 
 9 
autoantibodies. Some may not have evidence or markers for 
autoimmune process and they might have developed insulin 
deficiency due to idiopathic or non-immune mechanism. 
           
 The Autoimmune pancreatic pathology in development 
of T1DM is evident from pathological changes in pancreas 
of persons with impaired fasting glucose and impaired 
glucose tolerance. It is characteristically shows
8  
 
 Inflammatory cell infiltration  of Islet cell such as   - 
 Activated macrophages 
 Helper T cells  
 Cytotoxic T cells  
 Suppressor T cells 
 NK Cells 
 B Lymphocytes   
 Selective destruction of Beta cells sparing cells that 
secrete Glucagon and other hormones.  
 Patchy lesion with infiltrated lobules amidst 
unaffected lobules.  
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T1DM may co-exist with Auto immune diseases such as  
 Autoimmune thyroiditis 
 Coeliac disease 
 Addisons disease 
 Pernicious anaemia 
 Vitiligo 
 Which further support pathological mechanism of 
Autoimmunity in the etiopathogenesis of T1DM.  
 
Clinical course of type I DM: 
 At birth, all individuals have normal beta cell mass, 
later as age advances they lose their beta cell mass due to 
autoimmune mechanism, which is initiated by some 
environmental or infectious stimuli, that demands increased 
insulin requirement 
 
 Until 70%  - 80% of beta cells are destroyed, the 
individuals will be asymptomatic. As age and 
immunological processes advances, the percentage of 
destroyed beta cells reach a point at which the remaining 
viable beta cells are not enough to tolerate glucose load and 
they exhibit the clinical signs and symptoms.  
 11 
 Rate of destruction of beta cell mass varies with 
individuals. 
 
TYPE II DIABETES: 
 Two important pathological events that contributes to 
development of T2DM are  
- Insulin resistance 
- Defective insulin secretion 
 
 The  presence of these two events may not be 
sufficient to cause T2DM unless there is extensive beta cell 
dysfunction. This has led to the observation , where 
Genetics play a contributory role in the pathogenesis of 
T2DM. 
 
 Though Genetic factor is considered a special position 
in the etiology, the chance that a patient with Genetic 
susceptibility to develop Diabetes is largely decided by 
other factors such as 
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 Environmental factors 
 Social factors 
 Obesity 
 Diet 
 Age 
 Pregnancy 
 
 In fact insulin resistance occurs long before defective 
insulin secretion. T2DM manifests only after insulin 
secretion becomes defective.  
 
 It has a significant genetic association as evidenced 
by prevalence of insulin resistance in non-diabetic close 
relatives of T2DM patients. Other than genetic factors there 
are other factors that contr ibute to its development.  
 Obesity 
 Sedentary lifestyle 
 Food habits  
 The culprit genes are not yet completely identified. But 
recent studies have identified some associate genes such 
as  
 13 
 1Transcription factor 7- like 2 gene 
Genetic polymorphism of genes encoding,  
 PPAR-  
 Zinc transporter 
 IRS 
 Calpain10 
are associated with T2DM. 
 
1
DIAGNOSTIC CRITERIA 
  Symptoms of diabetes plus random blood glucose 
concentration  of 11.1 mmol/L (200 mg/Dl or more)or 
  Fasting plasma glucose 7.0 mmol/L (126 mg/dL or 
more)or  
  Two-hour plasma glucose 11.1 mmol/L (200 mg/dL or 
more) during an oral glucose tolerance test using 75g 
anhydrous glucose 
  A1C > 6.5% 
 
 Diabetic men have two times the risk of adverse 
cardiovascular events than non-diabetic control group. In 
women , the risk is three times in diabetic group than non-
diabetic control group.
2
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 Cardiovascular risk factors such as obesity and 
hypertension are co- existing in a higher frequency and 
level in diabetic than non-diabetic.
5,9-16
. This contributes to 
the increased risk and occurrence of adverse cardiovascular 
events in Diabetics than control group with  conventional 
risk factor alone. 
 
 In addition to this , there is a significant difference in 
the serum levels of HDL , LDL and VLDL between 
Diabetics and Non Diabetic group, where HDL is low and 
LDL ,VLDL are high in Diabetics when compared to non 
diabetics in whom HDL is higher and LDL ,VLDL is lower 
than the Diabetic group.
2
 
 
 There are still other studies which confers only little 
correlation between the quantitative status of the risk factor 
and the occurrence of Adverse cardiac events , which has 
individual variation both in diabetic and non-diabetic.
2
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DIABETES & INFLAMMATION 
 Inflammation plays an important role in the evolution 
of T2DM. Diabetes is now linked with chronic 
inflammatory state and this has been attributed to abnormal 
lipid metabolism
1
. 
 
  Insulin mediates its action by binding to insulin 
receptor in the surface of the Insulin responsive cells. The 
receptor in turn gets phosphorylated by itself and insulin 
receptor substrate family. This marks the initiating event in 
downstream signaling pathway.  
 
 Recent studies have shown some metabolic 
components involved in interference of signalling pathway. 
For instance in obesity metabolic overload puts 
endoplasmic reticulum in an incapacitant state. This 
burden, that is inflicted upon endoplasmic reticulum, 
activates inflammatory signal pathway and finally leading 
to Insulin resistance.
17,18 ,19
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 Another mechanism by which metabolic factor 
involves in this inflammatory pathway is increased 
production of Reactive oxygen species by mitochondria in 
obesity leading to enhanced activation of inflammatory 
pathway.
20,21
 
 
 Obesity and diabetes share common features of insulin 
resistance. In obesity there will be excessive accumulation 
of saturated fat in white adipose tissue resulting in 
increased synthesis and release of saturated fatty acids and 
TNF-α.  
  
 High level of free fatty acid and TNF-α activates 
inhibitory phosphorylation of serine residues of IRS – 
I
22,23
. This inhibits insulin stimulated tyrosine 
phosphorylation of IRS-I to interact with insulin receptor. 
This results in inhibition of insul in action
22,24 ,25
. 
                       
 Development of insulin resistance, T2DM and 
cardiovascular disease to a great extent are mediated by 
inflammatory processes. This is evident from high levels of 
circulating inflammatory markers such as CRP, cytokines, 
 17 
fibrinogen, IL-6, IL-8, PAI & TNF-α seen in T2DM 
patients
21
 . 
  
 Visceral obesity, which is common in diabetes leads 
to excess adipose tissue producing various adipokines 
including inflammatory cytokines. These inflammatory 
agents are a key component to the development of IR,  
obesity, diabetes
21
, atherosclerosis, heart disease and fatty 
liver. 
 
DIABETES COMPLICATIONS 
 Prolonged hyperglycaemia seen in diabetic is a key 
feature which poses deleterious effect in the human body.  
  
 Its adverse effects affecting the vascular anatomy are 
main events contributing to micro vascular and macro 
vascular diseases. 
 
COMPLICATIONS OF DIABETES :  
  Acute 
 Diabetic ketoacidosis 
 Hyperglycemic hyperosmolar state  
 18 
 Hypoglycemia 
 Diabetic coma 
 
  Chronic 
Microvascular : 
 Diabetic cardiomyopathy 
 Diabetic nephropathy 
 Diabetic neuropathy 
 Diabetic retinopathy 
 
Macrovascular disease :  
 Coronary artery disease 
 Diabetic myonecrosis 
 Peripheral vascular disease, 
 Stroke 
 
Both Microvascular and Macrovascular :  
          Diabetic sexual dysfunction 
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MICROVASCULAR COMPLICATION :  
Pathogenesis 
 The development of micro vascular complication 
depends on degree and duration of hyperglycaemia. Four 
possible mechanismshave been postulated. They are  
- Metabolic overload in form of excess Sorbitol and 
other Polyols within the endothelial layer.  
- Increased production of Prostaglandin products as a 
result of up regulation of Protein kinase C.  
- Nonenzymatic glycosylation of protein leading to 
increased production of advanced glycation end 
products and thereby increased production of TGF β.  
                
  Consequently all these factors lead to Glucose 
mediated oxidative damage.  
                
 However there are still some studies which contradict 
the role of Hyperglycaemia in the aetiopa thogenesis of 
diabetic complications. This fact was arrived from a study, 
where 40 % of the Diabetics even after meticulous optimal 
Glycaemic status develop Neuropathy eventually.
27
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 This holds the same for development of Nephropathy, 
where some study shows progression to Nephropathy 
despite good Glycaemic control.
28
 
 
MICROVASCULAR COMPLICATIONS 
Diabetic retinopathy 
 It is the commonest micro vascular complication. 
Degree of hyperglycaemia and its duration predicts the risk 
of developing retinopathy. Development of diabetic 
retinopathy in T2DM may also  require other risk factor 
such as hypertension. 
  
 The process of diabetic retinopathy starts well before 
the diagnosis of T2DM was made in T2DM patient
1  
. 
 
Proposed mechanism  
          Increased concentration of Sorbitol, which is a 
glucose alcohol derived from Glucose by POLYOL pathway 
is one mechanism. Here high sorbitolconcentration lead to 
osmotic stress which is thought to be the basic mechanism 
in most micro vascular complication including Diabetic 
Retinopathy. 
 21 
Other postulated mechanisms are  
- Oxidative stress by production of free radicals and 
reactive Oxygen species 
 
Increased production of  
- Growth factors such as Vascular Endothelial derived 
Growth factor. 
- Growth Hormone 
- TGF β  
- Product of advanced glycosylated end product 
  
 The role of Vascular endothelial growth 
factor
29,30 ,31and TGFβ are also implicated as evidenced by 
certain studies. 
. 
 Diabetic retinopathy can have major impact on the 
patient to the extent of blindness, especially if proliferativ e 
retinopathy sets in. so close monitoring for diabetic 
retinopathy is needed. 
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Diabetic nephropathy 
 It is characterised by proteinuria of more than 500ms 
in 24 hours in diabetic patients. Usually it follows micro 
albuminuria, where there is excretion of  albumin of 30-
300mg/day. 
  
 Micro albuminuria starts well early in the clinical 
span of T2DM. soit is prudent to screen for micro 
albuminuria very early, as 7% of T2DM patients are 
positive for micro albuminuria at diagnosis.  
  
 If no intervention has been taken during the time of 
micro albuminuria, the disease will worsen to proteinuria 
and finally end in diabetic nephropathy. ACEI therapy 
retards the progression to nephropathy in T2DM and 
prevent them in type I DM
32,33
. So ACEI is considered in 
the first line management of micro albuminuria, even in 
normotensive patient
33
. 
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Diabetic neuropathy  
 It is often unrecognised micro vascular complication 
of diabetes. 
  
 Peripheral neuropathy of diabetes is often a diagnosis 
of exclusion. Numerous works up is  necessary to arrive at 
the diagnosis of diabetic neuropathy.  
  
 In some people often present with foot ulcer before 
diagnosis is made. It accounts for more than 80% of 
amputation
34
. Exact mechanism by which diabetes causes 
neuropathy is not known, but the  risk of diabetic 
neuropathy has a linear relationship with degree and 
duration of diabetes 
 
 Distal symmetric sensorimotor polyneuropathy is the 
commonest type of neuropathy. Patient gives a history of 
tingling, burning pain or numbness. There is involvement 
of posterior column as evidenced by hypoaesthesia to total 
sensory loss to light touch, temperature and vibration. 
Ankle reflex is absent
34
. Diabetes with sensory loss to 10-g 
monoplanes are more prone for foot ulcer.  
 24 
Other types 
 Pure sensory neuropathy 
 Mononeuropathies 
 Diabetic amyotrophy34  
 Autonomic neuropathy 
 
NCS shows reduction in amplitude and conduction of nerve 
impulse. 
 
Differential diagnosis
34 
 Hypothyroidism 
 Vitamin B12 deficiency 
 Chronic inflammatory polyneuropathy 
 Uraemia  
  
 Glycaemic control is main treatment strategy to 
prevent and to retard the progression of diabetic 
neuropathy. Other contributing factors such as high blood 
pressure and dyslipidemia should be corrected
1  
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MACROVASCULAR COMPLICATION 
 The key underlying pathological mechanism that leads 
to the development of macro vascular disease is 
atherosclerosis. 
 
 The process involves injury to endothelium by chronic 
inflammatory process causes deposition and aggregation of 
oxidised lipids in LDL within the endothelial wall. This 
followed by monocyte infiltration and macrophage 
transformation. This process along with oxidised lipid lead 
to foam cell generation. Foam cell formation is followed 
by proliferation of macrophage and attraction of T-
lymphocytes which cause increased smooth muscle 
proliferation and collagen deposition.  
  
 Final product is atheromatous plaque rich in lipids 
with a fibrous envelope. Rupture of this plaque causes 
acute vascular occlusion. Diabetes have high incidence of 
plaque ulceration and intra coronary thrombus  formation
35
.  
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Other factor that contribute to vasculopathy are  
 Increased platelet adhesion 
 Hyper coagulopathy due to increased fibrinogen.  
 Increased free radical formation & platelet 
aggregation. 
 Increased PAI -1 
 
 So combined additive effects of pronounced 
coagulability and defective fibrinolysis cause the incidence 
of vascular obstruction and major adverse cardiac events to 
be higher in diabetes, especially T2DMpatients
36 
 
 Metabolic syndrome, comprising early spectrum of 
Diabetes as one of its components  poses a major risk factor 
for Atheromatous vascular disease.  
          
 It is a group of adverse medical events which when 
co-exist together enhances the occurrence of adverse 
cardiac events in addition to Diabetes. It is also known as  
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 Cardiometabolic syndrome 
 Syndrome X 
 Insulin resistant syndrome 
 Reaven‟s syndrome  
          
  Other conventional risk factors such as                  
smoking, obesity, Hypertension, Microalbuminuria, 
Hypercholesterolemia and increased lipoprotein (a) may 
coexist or some can be a consequent to it.  
             
 The number of risk factors in a person has a linear 
relationship with chance of developing major adverse 
cardiac events. In the presence of these factors Diabetes 
magnifies the adverse events caused by them.  
  
 Coronary heart disease is the commonest macro 
vascular complication in T2DM. 
                    
 Risk of Myocardial infarction in a person with 
Diabetic is same as that of a Non Diabetic with prior 
history of Myocardial infarction. Hence diabetes is 
considered as angina equivalent. Presence of diabetes 
 28 
confers a risk of MI equivalent to the risk of MI in a non -
diabetic with past history of MI.  
 
CORONARY ARTERY DISEASE 
 It is the most common heart disease. It is caused by 
narrowing of coronary arteries by atherosclerotic process. 
It is a chronic pathological process which begins in early 
life and manifests in early of late adulthood.  
  
 “Atherosclerosis” literally refers to localized 
aggregation of lipids and this affects the intimal layer of 
epicardial coronary artery thereby causing thickening of 
intimal layer.  
  
 Large and medium sized arteries are commonly 
involved. Atherosclerosis initiates inflammatory process in 
the vessel wall and cause endothelial dysfunction. This 
attracts lipids, cholesterol, inf lammatory cells and calcium 
within the intimal layer of blood vessel.  
  
 This leads to the genesis of plaque, which is made up 
of fat, cholesterol, calcium deposits and inflammatory 
 29 
cells. It starts as fatty streak which later develops into 
fibrous plaque, a lipid rich core composed of inflammatory 
cells, smooth muscle cells and cellular debris within it.  
 In patients with diabetes the inflammatory changes are 
marked. The degree of lipid composition in the plaque is 
more in diabetic CAD than non-diabetic CAD. Also there is 
increased inflammatory cell infiltration and thrombosis in 
them when compared to non-diabetics with coronary artery 
disease
37 .  
  
 These atheromatousplaque accumulate progressively 
and in advanced stage of the process, it causes luminal 
obstruction. The hemodynamics of the coronary blood flow 
is affected and there is reduced oxygen supply to the 
organs. Myocardial oxygen supply cannot meet increasing 
demands during exertion initially.  
 
 There is enough evidence to suggest high incidence of 
coronary artery disease in patients with conventional risk 
factors
38
 such as 
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 Smoking  
 obesity                                                                              
 Dyslipidemia (increased LDL) 
 Hyperfibrinogenemia& increased factor VII 39  
 Hyperlipoprotein (a)40 
 Hepatic lipase41 
 Advancing age 
 
 The role of alcohol in the causation of atherosclerotic 
coronary artery disease is controversial. Though alcohol 
causes altered metabolism, a mild to moderate intake of 
alcohol has been associated with decreased  incidence of 
adverse cardiac events such as CAD
4 2  
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Micrograph of a coronary artery with marked 
atherosclerosis and luminal narrowing.  
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Pathophysiology of  Atherosclerosis  
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 The role of alcohol in the causation of atherosclerotic 
coronary artery disease is controversial. Though alcohol 
causes altered metabolism, a mild to moderate intake of 
alcohol has been associated with decreased incidence of 
adverse cardiac events such as CAD.
42  
 
 Aerobic exercise reduces the risk of coronary art ery 
disease. This is supported by some studies where reduction 
in the serum level of lipids and inflammatory markers such 
as C-reactive protein, fibrinogen were observed after an 
aerobic exercise program.
43  
 
 The pathological mechanisms by which some risk 
factors lead to coronary artery disease are mediated through 
fibrinogen in common. This is evidenced by some studies 
which showed higher level of fibrinogen in smokers
44  
and 
in diabetics
45
. 
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CLINICAL MANIFESTATION: 
 Coronary artery disease has diverse clinical symptoms 
and signs
46
 ranging from stable angina to sudden death. 
Depending upon the anatomical viability of atheromatous 
plaque. 
  
 Chest pain with diaphoresis is the most common 
presentation. A typical anginal pain is that of  a retrosternal 
pain with a sense of heaviness, brought on exertion 
radiating to the neck, lower jaw, left shoulder, left arm or 
epigastrium and is relieved by rest and nitrates in stable 
angina. 
  
 But however this typical symptom need not be present 
always. They may have other symptoms which appear 
unrelated. They are termed angina equivalents.  
Anginal equivalents are
46  
 Dyspnea  
 Diaphoresis  
 Fatigue  
 Atypical chest pain 
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INVESTIGATION: 
 Patients basic investigations such as complete blood 
count, Thyroid function test, Fasting lipid profile and 
Glycemic status should be ascertained by fasting and 
postprandial blood sugar. Patients should be subjected to 
ECG both at rest and during stress. Cardiac evaluation 
using ECHO should be done, Thallium scintiography and 
CT Coronary Angiogram should be done where feasible.  
 
DIABETES AND FIBRINOGEN IN CORONARY 
ARTERY DISEASE: 
 As diabetes and fibrinogen share most of the 
conventional risk factor
38
 such as obesity, smoking, 
dyslipidemia, etc. contribution of diabetes and 
hyperfibrinogenemia
45
 together causes significantly 
increased risk of atherosclerotic coronary artery disease.  
          
 Role of fibrinogen in Atherosclerosis and Thrombosis 
has been postulated due to 
46
 factors given below 
 Magnified aggregation of platelet.  
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 Escalated Fibrin synthesis.  
 Increased vascular smooth muscle cell proliferation.  
       
 So Hyperfibrinogenemia causes Atherothrombosis of 
varying degree depending upon its level.  
 
FIBRINOGEN 
 Fibrinogen is a key component in coagulation process. 
It is a glycoprotein synthesized in liver by liver cells. It is 
about 340 kDa. Its normal serum level is 1.5 – 4.0 g/L. 
 
 It has an important role in final path of coagulation 
cascade where thrombin converts fibrinogen to fibrin. This 
fibrin is cross linked by factor VIII to form a clot. 
Thrombin and t-PA activates factor VIII and this is 
catalyzed by fibrin
47 .  
 
 Factor Xa and thrombin, which is involved in 
fibrinolysis, are transiently inhibited by fibrin, which 
engulf them within the fibers. There they remain viable to 
be released during fibrinolysis
48 .  
 37 
.  
 
COAGULATION CASCADE :  
 
 
Fibrinogen deficiency 
  It can be congenital or acquired.  Congenital 
deficiency is rare and been reported in few.  
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Dysfibrinogenemia 
         Gene controlling synthesis of Fibrinogen in liver  
undergoes mutation and causes Dysfibrinogenemia, a rare 
coagulopathic condition.  
           
 It causes failure of degradation of fibrinogen,while  
being  converted to fibrin. These patients are prone for 
venous thrombosis and bleeding in rare instance.  
Genetic molecular testing is used to detect the culprit 
genetic mutation, responsible for  
 Inherited Dysfibrinogenemia 
 Hypofibinogenemia  (or)  
 Afibrinogenemia 
. 
Causes of Acquired deficiency  
 Sepsis 
 Severe trauma with extensive tissue loss  
 Disseminated intravascular coagulation 
 Massive blood loss 
 Post Hemodilution.  
 Drugs 
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- Anabolic steroids 
- Phenobarbitol 
- Streptokinase 
- Valproic acid 
 
Estimation of Fibrinogen 
        It can be ascertained using venous blood. Normally it 
ranges from 1.5 – 4 g/L depending upon the laboratory 
method adopted. It can be estimated with blood serum or 
plasma. 
       
  In plasma, it is measured by CLAUSS method which 
shows an inverse relationship between clotting time and 
plasma Fibrinogen level.  
 
 Fibrinogen level increases with BMI, smoking,  fasting 
insulin levels, LDL,WBC Count, Diabetes and Pregnancy.  
Whereas it is reduced in moderate alcohol usage, exercise, 
high level of high density lipoprotein and hormone 
replacement therapy 
49,50 ,51  
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 Fibrinogen poses significant risk for cardiovascular  
disorders.
52,53 . It‟s positive relationship with BMI has been 
established by a study which showed decrease in fibrinogen 
level following low calorie healthy diet for 6 months 
54
 and 
this may be the mechanism by which obesity increases the 
risk of cardiovascular disease. Also fibrinogen level are 
high in diabetes
55
 than controls.  
 
 Obesity can be a link between diabetes and fibrinogen 
in causing adverse cardiac event mediated by fibrinogen 
and other traditional cardiovascular risk factor such as 
BMI, obesity, etc.  
 
 Poor glycemic status are often associated with 
increased fibrinogen level
(56)
 and this is evidenced by the 
observation of  increased platelet reactivity in Diabetics 
and this may be due to high fibrinogen level which cross 
bridges platelets.  
 
 Fibrinogen as a predictor of adverse coronary events 
in angina patients has been established by a study 
conducted by Thompson &colleagues
57
. This further 
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establishes T2DM as a high risk event for cardiovascular 
disease.
58,59 
 
 Increased risk for cardiovascular disease in smokers 
can be attributable to high level of fibrinogen found in 
smokers than in non-smokers. This association has been 
established by study conducted by Fogari et al
60  
which 
showed a linear relationship between fibrinogen level and 
number of cigars smoked. 
 
 It is well established that Diabetes have increased risk 
of adverse cardiac events. Plaque rupture and thrombosis 
are the key components in acute coronary syndrome. 
Pathogenesis of these events are largely contributed by 
inflammatory pathology as evidenced by increased level of 
fibrinogen and C-reactive protein in patients with unstable 
angina
61
. 
 
 A study by Emansh et al, suggest a strong link 
between high plasma fibrinogen level and Premature 
CAD
62
.Role of Fibrinogen in the causation of 
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Atheroembolic events is further accomplished by several 
studies showing strong link between Fibrinogen level and  
 Ischemic Cerebrovascular accident 63,64 ,65 
 Peripheral vascular disease66,67 
 
 Fibrinogen, an acute phase reactant and a 
procoagulant in addition,  is being centered around the 
pathophysiology of atherosclerosis. Hence it is being 
considered as a significant factor in the pathogenesis of 
coronary artery disease, especially in T2DM patients where 
its serum level is higher than non diabetic populat ion. 
 
 Recently the role of fibrinogen level in serum in 
predicting subsequent major adverse cardiac events in  
known Diabetics with coronary artery disease patients is 
being studied extensively .  
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MATERIALS AND METHODS  
 
Study site 
 Department of General  Medicine, Government Stanley 
Medical college and Hospital, Chennai.  
 
Collaborating Departments  
 Department of Cardiology 
 Department of Medical Biochemistry  
 
Study Design 
 - Cross sectional study  
 
Study Period 
 - June 2012 to November 2012  
 
Selection of study population 
 - Inclusion criteria 
 
 Diabetic inpatients with past history or evidence of 
Coronary artery disease.  
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Exclusion Criteria 
 Disseminated intravascular coagulation 
 Pregnancy 
 Liver disease 
 Sepsis 
 Drug abuse like OCP,Antifibrinolytic, hormones  
 Dysfibrinogenemia 
 
Investigations done 
 Complete blood count 
 Blood sugar – Random, fasting and post prandial  
 Glycosylated Hb 
 Blood urea 
 Serum creatinine 
 Urine routine analysis  
 ECG 
 ECHO 
 Serum fibrinogen 
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Sample size  
 Using the above mentioned criteria 50  subjects were 
recruited 
Sampling method 
 Convenience sampling method was adopted 
 
Study protocol 
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Estimation  of Serum fibrinogen 
Clauss method 
 The determination of fibrinogen with thrombin 
clotting time is based on the method originally described b y 
Clauss; in the presence of an excess of thrombin, fibrinogen 
is transformed into fibrin and clot formation time is 
inversely proportional to the concentration of fibrinogen in 
the sample plasma. 
 
Reagents  
Fibrinogen reference 
 Lyophilized human plasmacontaining buffer and 
preservative 
 
Thrombin reagent 
 Lyophilized preparation containing bovine thrombin, 
approximately 75 NIH U/ml, buffer, stabilizers and 
preservative 
 
Imidazole buffer 
 Imidazole 30 mmol/L 
 Sodium chloride 125 mmol/L 
 Sodium azide 0.1% as preservative, pH 7.35 
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Sample 
 Venous blood collected in 3.8% sodium citrate in a 
ratio of 9 parts of blood to 1 part of 
anticoagulant(1:10) 
 
Procedure 
 Reconstitution of Thrombin agent done and maintained at 
room temperature(18-26
○
C) during testing 
 To the fibrometer cup 0.2ml of the diluted plasma sample 
added 
 To the fibrometer cup 0.2ml of the diluted plasma sample 
added 
 This is incubated for 1-3 minutes at 37○C for not more 
than 5 minutes 
 After incubation 0.1 ml of Thrombin reagent is added 
rapidly into the fibrometer while simultaneously starting 
the timer 
 Clotting time results recorded in seconds  
 Extrapolation of concentration done from calibration 
curve 
 Results evaluated and tabulated 
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Major adverse cardiac events 
 Recurrent angina(RA) 
 Congestive cardiac failure(CCF) 
 Arrhythmia(AR) 
 Death(CD) 
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RESULTS 
 
 This study was done to correlate the plasma 
fibrinogen levels in major adverse cardiac events occurring 
in known diabetic coronary artery disease patients who 
were admitted as in patients in Department of Medicine, 
Government Stanley Medical College, Chennai.  
Age distribution 
Chart 1 
 
 The total number of study subjects is N=50. Among 
them the age distribution ranges from 44 to 78 years. The 
majority of the patients belonged to the 44-78 years age 
group (42%) (Chart 1) 
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Gender distribution 
Chart 2 
 
 
 As far as the gender distribution is concerned 66% of 
the study subjects are males and 34% of them are females. 
(Chart 2) 
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Group wise distribution of study population 
demographic characteristics  
Table 1 
 No 
MACE 
(n=24) 
Recurrent 
Angina 
(n=11) 
Congestive 
Cardiac 
Failure 
(n=15) 
Arrhythmia 
(n=0) 
Death 
(n=0) 
Age  57.33 63.92 65.2 0.00 0.00 
Duration 
of 
Diabetes 
11.4 13.54 15.55 0.00 0.00 
Fasting 
Blood 
Sugar 
139.78 187.85 213.68 0.00 0.00 
Post 
Prandial 
Blood 
Sugar 
250.87 299.54 332.18 0.00 0.00 
HBA1 C  9.22 9.98 10.03 0.00 0.00 
Serum 
Fibrinogen 
306.07 344.08 426.32 0.00 0.00 
 
Table 1 displays the demographic data with mean values of 
age of patients, duration of diabetes, fasting blood sugar, 
post prandial blood sugar, glycosylated haemoglobin 
(HBA1C) and serum fibrinogen levels.  
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 The mean values have been matched against the major 
adverse cardiac events (MACE) groups – recurrent angina, 
congestive cardiac failure, arrhythmia and death. Patients 
who do not develop MACE are captured in a separate 
group. 
 
Prevalence of Major Adverse Cardiac Events  
Table 2 
MACE No of Patients Percentage (%) 
No MACE 24 48 
Recurrent Angina 11 22 
Congestive cardiac 
failure 
15 30 
TOTAL  50 100 
 
 The observations made by Table 2 suggests that, the 
highest prevalence is that of patients who do not develop 
MACE(48%). This group is followed by the congestive 
cardiac failure group (30%). Arrhythmia and death groups 
will no longer be considered in this study due to no 
responses. 
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Relationship between MACE and patient age  
Table 3A 
Age  40-49 50-59 60-69 70-79 TOTAL 
No MACE 5 11 9 1 26 
Recurrent 
Angina 
1 1 3 2 7 
Congestive 
cardiac 
failure 
0 2 9 6 17 
 
TOTAL  6 14 21 9 50 
X
2
= 17.97  P=0.0063 
From Table 3A the following observations can be made: 
 26 patients did not suffer from MACE 
 7 had recurrent angina and 17 had congestive cardiac 
failure 
 In the group which did not have MACE more numbers 
clustered around the age groups of 50-59 and 60-69 
 RA group has more numbers clustered around 60-69 age 
group 
 Similarly the CCF group is clustered around 60-69 age 
group 
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Statistical Comparisons 
Table 3B 
Comparisons ‘t’  ‘p’  
No MACE - Recurrent Angina 2.77 <0.001 
Recurrent Angina - Congestive 
cardiac failure 
0.83 >0.05 
Congestive cardiac failure - No 
MACE 
4.44 <0.001 
 
 From Table 1 it can be seen that the mean ages of 
study groups No MACE, AR and CCF are 57, 64 and 66 
respectively. 
 
 The above mentioned mean age groups were compared 
with each other as shown in table 3B using Student‟s 
unpaired t test. 
  
 On comparison of the No MACE and RA group a p 
value of <0.001 was arrived at and similarly comparing the 
age groups of RA and CCF yield a p value of <0.001 both 
highly significant. 
 55 
Relationship between MACE and sex of the patient  
Table 4 
 Male  Female  TOTAL 
No MACE 20(40%) 8(16%) 28 
Recurrent Angina 4(8%) 4(8%) 8 
Congestive cardiac 
failure 
9(18%) 5(10%) 14 
TOTAL  33(66%) 17(44%) 50 
X
2
= 2.37   P=0.305 
Table 4 revealed the following details:  
 In the No MACE group there were 20 men and 8 
women 
 The RA group consisted of 4 men and 4 women  
 CCF group had 9 men and 5 women 
 In total there were 33 men and 17 women  
 The numbers when analysed statistically, yielded a chi 
squre value of 2.37 and a p value of  0.305(not 
significant) 
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Relationship between MACE and duration of Diabetes  
Table 5 
 5-10y 11-15y >15y TOTAL 
No MACE 6 19 4 29 
Recurrent 
Angina 
1 2 5 8 
Congestive 
cardiac 
failure 
1 3 9 13 
TOTAL  8 24 18 50 
X
2
= 14.87  P=0.005 
From Table 5 the following can be gathered  
 No MACE group consists of 29 patients and clustering 
is seen in the 5-10 and 11-15 years duration group 
 In contrast RA group showed only 1 patient who 
developed recurrent angina within 10 years of 
diabetes and majority developed it after 15 yearsof 
diabetes 
 CCF group showed the same picture as RA group 
 Chi square test was used to analyse and revealed a p 
value of 0.005(statistically significant)  
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Relationship between MACE and Fasting blood sugar  
Table 6 
FBS(mg/dl) 90-140 141-190 191-240 241-290 TOTAL 
No MACE 15 11 0 0 26 
Recurrent 
Angina 
0 3 4 0 7 
Congestive 
cardiac failure 
0 1 9 7 17 
TOTAL  15 15 13 7 50 
X
2
= 56.30  P= <0.0001 
From the above table, it can be seen that:  
 Majority of the patients in the No MACE group 
belonged to the FBS 90-140 range 
 In the RA group, highest number of patients belonged 
to FBS 191-240 range 
 In the CCF most of the clustering was around 191-240 
and 241-290 range 
 However the last FBS group, 241-290 range had only 
7 patients 
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Relationship between MACE and Post Prandial blood sugar  
Table 7 
PPBS 190-240 241-290 291-340 341-390 TOTAL 
No MACE 12 8 5 0 25 
Recurrent 
Angina 
0 2 4 0 6 
Congestive 
cardiac 
failure 
0 1 7 7 15 
TOTAL  12 11 16 7 50 
X
2
= 55.69  P= <0.0001 
It can be seen from this table:  
 Among the No MACE group, large number of patients 
belong to the 190-240 and 241-290 PPBS range. 341-
390 range did not have any patients.  
 RA group shows 4 patients in 291-390 range and nil 
patients in 190-240 and 341-390 ranges  
 CCF group shows equal presence of patients in 291-
340 and 341-390 range 
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Relationship between MACE and Glycemic control  
Table 8  
 Well 
controlled 
Uncontrolled TOTAL 
 HBA1C 6.2-
8.3 
HBA1C>8.3  
No MACE 20 8 28 
Recurrent 
Angina 
1 7 8 
Congestive 
cardiac 
failure 
0 14 14 
TOTAL  9 41 50 
X
2
= 8.21  P= <0.0165 
 From this table it can be clearly seen that more 
patients under the No MACE group are under the well -
controlled H BA1Cgroup(20 out of 28). But in the RA and 
CCF groups very few patients are under the well -controlled 
H BA1C group (1 and 0 respectively). The category of 
poorly maintained H BA1C group has the largest number of 
patients (41 out of 50). Chi square test was used to analyse 
and revealed a p value of 0.0165(statistically significant)  
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Relationship between Serum Fibrinogen levels &patient age 
Table 9 
Serum 
Fibrinogen(mg/dl) 
Age of the patient (years) 
40-49 50-59 60-69 70-79 
200-250 1 0 1 0 
251-300 1 4 1 1 
301-350 3 7 3 1 
351-400 0 1 1 0 
>400 1 3 15 6 
 6 15 21 8 
X
2
= 3.47  P= >0.05 
 The serum fibrinogen levels were recorded in 50 
patients with major adverse cardiac events. It can be seen 
that serum fibrinogen levels 200-250 range has only 1 
patient in 40-49 and 60-69 age groups with other groups 
recording nil entries. In the serum fibrinogen levels 251 -
300 category, majority of the patients are seen in the 50 -59 
age groups.  Similar picture is reflected in serum fibrinogen 
levels category 301-350. There are nil patients in the age 
groups 50-59 and 60-69 under serum fibrinogen levels 
category 351-400. In contrast serum fibrinogen levels 
category >400 shows the highest number of pat ients in the 
60-69 age group. 
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Relationship between Serum Fibrinogen levels and sex of 
the patient 
Table 10 
 Mean serum fibrinogen 
(mg/dl) 
 
 Male  Female  P value 
No MACE 299.71 311.29 0.29 
Recurrent 
Angina 
349.33 339.57 0.64 
Congestive 
cardiac failure 
431.39 419.00 0.41 
 
 It can be seen from the above table that, among the 
No MACE group, the women had a mean serum fibrinogen 
level of 311, while the men had a mean serum fibrinogen 
level of nearly 300. In the RA group, , the women had a 
mean serum fibrinogen level of 339, while the men had a 
mean serum fibrinogen level of 349. Finally in the CCF 
group , the women had a mean serum fibrinogen level of 
419, while the men had a mean serum fibrinogen level of 
431. The three groups had p values of 0.29, 0.64 and 0.41, 
all of them not statistically significant.  
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Relationship between Serum Fibrinogen levels and 
duration of Diabetes 
Table 11 
Mean serum fibrinogen 
(mg/dl) 
No of cases according to 
duration of disease 
 5-10 11-15 >15 
No MACE 6 19 4 
Recurrent Angina 1 2 5 
Congestive cardiac failure 1 3 9 
Mean serum fibrinogen 319 337 375 
X
2
= 14.87  P=0.01 
Table 11 reveals the following 
 Patients with diabetes for 5-10 years have a mean 
serum fibrinogen level of 319 mg/dl with maximum 
patients having no MACE 
 Patients with diabetes for 11-15 years have a mean 
serum fibrinogen level of 337 mg/dl with maximum 
patients having no MACE 
 Patients with diabetes for more than15 years have a 
mean serum fibrinogen level of 375 mg/dl with 
maximum patients in the CCF group 
 63 
 Statistical comparisons yielded a chi square value of 
14.87 and p value of <0.01(statistically significant)  
 
Relationship between Serum Fibrinogen levels and 
Fasting blood sugar 
Table 12A 
FBS 90-140 141-190 191-240 241-290 
Mean 
serum 
fibrinogen 
298.71 333.31 406.62 424 
No of 
Cases 
15 21 12 2 
 
Statistical comparisons 
Table 12B 
Comparisons  Z value P 
value 
 
(90-140) – (141-190) 3.46 <0.01  
(141-190) - (191-240) 5.22 <0.001  
(191-240) - (241-290) 1.3 >0.05  
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From the above table, it can be seen that:  
 15 patients belonged to the FBS 90-140 range with 
mean serum fibrinogen kevel of 299 mg/dl nearly  
 21 patients belonged to the FBS 141-190 range with 
mean serum fibrinogen kevel of 333mg/dl  
 12 patients belonged to the FBS 191-240 range with 
mean serum fibrinogen kevel of 406 mg/dl 
 2 patients belonged to the FBS 241-290 range with 
mean serum fibrinogen kevel of 424 mg/dl  
 Statistical comparisons were performed between 
categories (90-140) – (141-190), (141-190) - (191-
240) and (191-240) - (241-290). The z value obtained 
was 3.46, 5.22 and 1.3 respectively. The 
corresponding p values were <0.01, <0.001(both 
statistically significant) and >0.05  
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Relationship between Serum Fibrinogen levels and Post 
Prandial blood sugar 
Table 13A 
PPBS 190-240 241-290 291-340 341-390 
Mean 
serum 
fibrinogen 
295.77 332.1 365.18 425.1 
No of 
Cases 
13 12 18 7 
 
 
Statistical comparisons 
Table 13B 
Comparisons  Z value P value  
(190-240) – 
(241-290) 
2.9 <0.01  
(241-290) - 
(291-340) 
2.15 <0.05  
(291-340) - 
(341-390) 
3.81 <0.001  
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From the above table, it can be seen that:  
 13 patients belonged to the PPBS 190-240 range with 
mean serum fibrinogen kevel of 295.77 mg/dl  
 12 patients belonged to the PPBS 241-290 range with 
mean serum fibrinogen kevel of 332mg/dl  
 18 patients belonged to the PPBS 291-340 range with 
mean serum fibrinogen kevel of 365 mg/dl  
 7 patients belonged to the PPBS 341-390 range with 
mean serum fibrinogen kevel of 425 mg/dl  
 Statistical comparisons were performed between 
categories (190-240) – (241-290), (241-290) - (291-
340) and (291-340) - (341-390). The z value obtained 
was 2.9, 2.15 and 3.81 respectively. The 
corresponding p values were <0.01, <0.05 and 
<0.001(all statistically significant)  
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Relationship between Serum Fibrinogen and Glycemic 
control 
Table 14 
 Well 
controlled 
Uncontrolled TOTAL 
 HBA1C  6.2-
8.3 
HBA1C>8.3  
Mean 
fibrinogen 
values 
315.06 354.10 28 
No of Cases 11 39 8 
Z value 2.67 
P value <0.01 
 
 In this table, it is seen that mean serum fibrinogen 
value for the category of well controlled (11 patients) 
HBA1 C was 315.06, while the mean serum plasma 
fibrinogen value for the category of poorly controlled (39 
patients) HBA1C was 354.10. Statistical comparisons of 
mean serum fibrinogen values of the two categories yielded 
a z value of 2.67 and a p value of <0.001(s tatistically 
significant). 
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Relationship between Serum Fibrinogen levels and 
MACE 
Table 15A 
MACE No of Patients Mean serum 
fibrinogen levels 
No MACE 24 306.07 
Recurrent Angina 11 344.08 
Congestive cardiac 
failure 
15 426.32 
 
Statistical comparisons 
Table 15B 
Comparisons  „t‟ „p‟ 
No MACE - Recurrent 
Angina 
3.89 <0.001 
Recurrent Angina - 
Congestive cardiac failure 
6.63 <0.001 
Congestive cardiac failure 
- No MACE 
14.84 <0.001 
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Tables above reveal that  
 No MACE category has 24 patients with mean serum 
fibrinogen level of 306.07 mg/d 
 RA category has 11 patients with mean serum 
fibrinogen level of 344.08 mg/dl  
 CCF category has 15 patients with mean serum 
fibrinogen level of 426.32 mg/dl  
 Comparisons between mean serum fibrinogen levels of  
No MACE - Recurrent Angina category yielded a t 
value of 3.89 
 Comparisons between mean serum fibrinogen levels of  
Recurrent Angina - Congestive cardiac failure 
category yielded a t value of 6.63  
 Comparisons between mean serum fibrinogen levels of  
Congestive cardiac failure - No MACE category 
yielded a t value of 14.84 
 All of the comparisons had a p value of <0.001  
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DISCUSSION 
 
 The present study, which is cross sectional in design, 
has a sample size of 50 patients of Diabetes mellitus with 
coronary artery disease. Among the 26 patients with major 
adverse cardiac events 11 had recurrent angina (22%)  and 
15 had congestive cardiac failure(30%).  
 
 The relationship between patient age and major 
adverse cardiac events among 50 patients were obtained 
from table 3. They revealed that the severity of major 
adverse cardiac events increased with the increasing age of 
the patients in a statistically significant manner.  
 
 Although there is a higher number of males than 
females with regard to total number of patients, it is 
evident that there is no significant variation in major 
adverse cardiac events in relation to gender of the patient  
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 More patients with recurrent angina and congestive 
cardiac failure were among those patients with diabetic age 
more than 15 years(table 6). The findings prove that  
worsening of major adverse cardiac events with increasing 
duration of diabetes in these individuals is statistically 
significant. 
 
 Regarding the relationship of fasting blood sugar and 
post prandial blood sugar levels with the severity of major 
adverse cardiac events, it was observed that there is a 
statistically significant increase in the severity of major 
adverse cardiac events with increasing values of FBS and 
PPBS. 
 
  One of the studies conducted previously in this 
regard found that risk of major adverse cardiac events six 
times more among patients with poor glycemic control. 
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Serum fibrinogen is one of the important factors that leads 
to the increased viscosity of blood, especially in diabetics. 
It is known for its role in end organ diseases. In this study 
serum fibrinogen levels was compared with various 
parameters and statistically analysed. The observations and 
interpretations are as follows 
 
 No correlation found between the age of the patients 
and gender of the patients with their levels of serum 
fibrinogen  
 
 When serum fibrinogen levels were correlated with 
various parameters regarding the diabetic age, blood 
sugar and glycemic control, mean serum fibrinogen 
was found to be in correlation with all the above  
parameters. It means that with progression and 
increase in severity of diabetes, there is a noticeable 
rise in mean serum fibrinogen titres.  
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 This could be attributed to the reason that long 
standing and poorly controlled diabetes is associated 
with greater incidence of macro vascular pathologies. 
It is seen in a related study that serum fibrinogen 
levels were higher in those diabetics with poor 
metabolic control 
69
 
 
 There is a positive correlation between major adverse 
cardiac events and mean serum fibrinogen levels. 
Increase in severity of major adverse cardiac events 
causes simultaneous increase in serum fibrinogen. 
Other similar studies have concluded stating that 
fibrinogen may be involved in increased 
cardiovascular risk of patients with diabetes
70 ,58
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SUMMARY &CONCLUSION 
 
The summary of results obtained is as follows:  
 The study included 50 diabetic patients with coronary 
artery disease.  
 Age varied from 44 to 78 years  
 52% of the patients suffered from major adverse 
cardiac events(recurrent angina and congestive 
cardiac failure)  
 Older patients had more severe forms of major 
adverse cardiac events  
 There is no significance between gender of patients 
and severity of major adverse cardiac events  
 Longer the duration of diabetes more severe the major 
adverse cardiac events 
 Higher blood sugar levels and poorer glycemic control 
leads to severe major adverse cardiac events  
 No correlation between mean serum fibrinogen level 
and age or gender of the patient  
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 Mean serum fibrinogen levels was significantly higher  
in patients with longer duration of diabetes, higher 
blood sugars and poor glycemic control  
 Increase in severity of major adverse cardiac events 
correlates with increase in serum fibrinogen titres  
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AGE: 
 
IP NO: 
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SEX: 
 
UNIT: 
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ADDRESS: 
 
OCCUPATION: 
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 INVESTIGATIONS:                      
CBC: 
HB: 
PCV: 
TC: 
DC: 
ESR 
BLOOD SUGAR- RBS 
                             FBS 
                            PPBS 
Hb A1C: 
     FIBRINOGEN: 
     UREA: 
     CREATININE: 
     LIPID PROFILE: 
     URINE ROUTINE: 
 
ECG: 
ECHO: 
 
 
 
 
 
  
 MASTER KEY 
 
SBP  :  SYSTOLIC BLOOD PRESSURE 
DBP  :  DIASTOLIC BLOOD PRESSURE 
FBS  :   FASTING BLOOD SUGAR 
PPBS  : POSTPRANDIAL BLOOD SUGAR 
ECG  :   ELECTROCARDIOGRAM 
ECHO : ECHOCARDIOGRAM 
TC      : TOTAL CHOLESTROL 
LDL    : LOW DENSITY LIPOPROTEIN 
HDL    : HIGH DENSITY LIPOPROTEIN 
VLDL : VERY LOW DENSITY LIPOPRITEIN 
TGL : TRIGLYCERIDES 
MACE: MAJOR ADVERSE CARDIAC EVENT 
IWMI  : INFERIOR WALL MYOCARDIAL INFARCTION 
PRWP  : POOR R WAVE PROGRESSION 
EF       : EJECTION FRACTION 
T2DM  : TYPE 2 DIABETES MELLITUS 
SHT     : SYSTEMIC HYPERTENSION 
CAD    : CORONARY ARTERY DISEASE 
DCMP  : DILATED CARDIOMYOPATHY 
IDCMP : ISCHEMIC DILATED CARDIOMYOPATHY 
CCF      : CONGESTIVE CARDIAC FAILURE 
 RWMA  : REGIONAL WALL MOTION ABNORMALITY 
LVSE    : LEFT VENTRICULAR SYSTOLIC FUNCTION   
UA        : UNSTABLE ANGINA 
NSR      : NORMAL SINUS RHYTHM 
WNL     : WITHIN NORMAL LIMIT 
LVH      : LEFT VENTRICULAR HYPERTROPHY 
CKD      : CHRONIC KIDNEY DISEASE 
LVF       : LEFT VENTRICULAR FAILURE 
CVA       : CEREBRO VASCULAR ACCIDENT  
COPD     : CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
PT          : PULMONARY TUBERCULOSIS 
ADD       : ACUTE DIARRHOEAL DISEASE 
LL           : LOWER LOBE 
DD          : DIASTOLIC DYSFUNCTION 
GERD      : GASTRO ESOPHAGEAL REFLUX DISEASE 
RA           : RECURRENT ANGINA 
AR           : ARRRYTHMIAS 
CD           : DEATH 
OCP         : ORAL CONTRACEPTIVE PILLS 
COPD      : CHRONIC OBSTRUCTIVE LUNG DISEASE 
 
 
 
Albumin
nil=1
trace=2
1+=3
2+=4
3+=5
Sugar
nil=1
trace=2
1+=3
2+=4
3+=5
Duration of
Diabetes
inYears
Glycosyla
ted Hb TC LDL HDL VLDL TGL
1 Nagammal 44 1 140 96 1 3 5 178 233 182 292 6.1 Old IWMI,  PRWP in V1 - V3 Thin hypokinetic  mid
IW, EF 30%
151 87 45 19 99 21 0.7 462 T2DM/SHT/CAD/IDCMP/CCF 0
2 Palliappan 46 1 140 96 1 2 6 175 230 219 329 9.6 ST ↓ II,III, aVF No RWMA, Normal
LVSF
136 90 30 16 81 32 1.2 377.8 SHT/T2DM/COPD/CAD 0
3 Jayalakshmi 47 1 130 86 1 1 6 89 144 108 218 8.9 ST ↓ V2 - V5 Normal LVSF 131 87 28 16 81 17 0.8 395.2 T2DM/CAD/UA 0
4 Kothandaraman 47 1 140 94 1 1 6 120 175 162 272 8.4 NSR, WNL No RWMA, Normal
LVSF
120 68 30 22 77 35 0.9 380 T2DM/SHT/CAD/UA 0
5 Balakrishnan 47 1 160 102 2 4 7 155 210 210 320 9.1 NSR, LVH, ST ↓ & T wave ↓
V1 - V4
Global hypokinesia of
inferobasal wall, EF
32%
137 87 26 24 120 36 1.2 423 T2DM/ CAD/ DCMP/ CCF 0
6 Sivasamy 51 1 200 120 3 1 7 112 167 140 250 7.2 NSR,LVH with strain Concentric LVH 148 108 20 20 160 55 1.4 360 T2DM/CAD/CKD/Acc.HT/LVF 0
Diagnosis
MACE
NIL=0
RA=1
CCF=2
ARR=3
CD=4
Urine Fasting Lipd Profile
S.No. Name Age
Sex
male=1
female=
2
SBP DBP FBS S.FibrinogenECG EchoPPBS Urea CreatinineFBS PPBS
7 Selvam 52 1 150 94 1 1 8 120 175 160 270 8.8 NSR,LVH No RWMA,Conc.LVH 135 87 28 20 86 35 0.8 382 T2DM/CAD/Old CVA/UA 0
8 Mani 54 1 130 84 1 4 9 155 210 233 343 9.3 ST↓L2,L3 & Avf No RWMA,Normal
LVSF
138 90 30 18 90 40 1.1 374 T2DM/CAD/UA/Inferior wall
ischemia
0
9 Daniel 54 1 140 100 1 1 11 140 195 192 302 9.1 T↓L1,Avl, LVH No RWMA,Conc.LVH 137 88 30 19 104 50 1 375 T2DM/SHT/COPD/CAD/Recu
rrent angina
0
10 Purushothaman 55 1 140 90 1 4 11 140 195 182 292 7.8 T↓L1,aVL, V5,V6 No RWMA,Normal
LVSF
136 88 28 20 140 40 1 398 T2DM/CAD/UA/Lateral wall
ischemia
0
11 Thangappan 56 1 130 86 1 1 11 104 159 136 246 8.8 WNL Normal LV function 125 80 26 19 130 26 0.8 356 T2DM/CAD/UA 0
12 Mallika 56 1 160 94 1 4 11 10 65 200 310 8.5 NSR, LVH with strain pattern No RWMA, conc. LVH 141 98 20 23 160 36 0.9 364 T2DM/ CAD/ SHT/ LVF 0
13 Munusamy 56 1 130 90 1 1 11 102 157 136 246 9 NSR, LV strain pattern Hypokinesia of infero-
posterior segment of
LV, EF 46%
144 98 20 26 160 38 0.9 368 T2DM/ CAD/ LVF 0
14 Chinnasamy 58 1 168 96 2 3 11 130 185 184 294 6.9 NSR, LVH with strain pattern No RWMA, conc. LVH 112 60 30 22 160 36 1.2 392 T2DM/ SHT/ CAD/ LVF 0
15 Saleem Basha 58 1 130 86 1 1 11 120 175 184 294 8.4 NSR, no specific ST-T
changes
No RWMA, Normal LV
function
187 122 45 20 84 40 1 310 T2DM/CAD/ UA 0
16 Manalan 56 1 140 86 1 1 12 120 175 162 272 8.5 NSR, ST↓, T↓ I, avL, V5, V6 hypokinesia of
inferolateral segment
of LV, EF 50%
146 96 30 20 81 50 1 366 T2DM/ CAD/ OLD PT/ LVF 0
17 Punitha 55 1 130 86 1 1 12 102 157 156 266 8.1 NSR, T wave↓ avL V5 - V6 No RWMA, Normal LV
function
143 92 33 18 82 36 0.8 302 T2DM/COPD/ UA 0
18 Krishnamoorthy 57 1 172 96 3 4 12 146 201 220 330 9.2 NSR, LVH with strain pattern hypokinesia of mid
inferior wall, MR
trivial, EF 32%
145 98 28 19 168 38 1.2 392 SHT/T2DM/CAD/ LVF 0
19 Nagavalli 57 1 160 100 1 1 12 132 187 180 290 9.3 NSR, LVH with strain pattern No RWMA, Normal LV
function
113 68 25 20 102 42 0.9 388 T2DM/CAD/OLD IWMI/ LVF 0
20 Munusamy 57 1 200 100 1 3 12 132 187 198 308 9 NSR, LVH with strain pattern No RWMA, Normal LV
function
113 45 48 20 100 36 0.9 393.2 T2DM/ SHT/ CAD/ LVF 0
21 Buvana 59 1 140 92 1 1 12 112 167 136 246 9.1 NSR, no specific ST-T
changes
No RWMA, Normal LV
function
123 58 45 20 170 40 0.9 276 T2DM/ SHT/ CAD/ ADD 0
22 Kanniappan 61 1 150 88 1 1 12 130 185 156 266 8.9 NSR, Qs III, avF Hypokinesia of mid
inferior wall, EF 46%
160 98 40 22 170 38 1.1 292.2 T2DM/ Old IWMI/ fever for
evaluation
0
23 Valliammal 61 1 154 88 1 3 13 132 187 164 274 9 NSR, WNL No RWMA, Normal LV
function
140 90 30 20 90 38 1.1 280 T2DM/CAD/COPD
EXACERBATION
0
24 Muthappan 61 1 148 86 1 1 13 107 162 148 258 8.8 NSR, WNL No RWMA, Normal LV
function
141 80 42 19 132 46 1 274.3 T2DM/CAD/COPD CHRONIC
BRONCHITIS
0
25 Pushpa 61 1 160 92 3 4 13 136 191 180 290 9.1 NSR, no specific ST-T
changes
No RWMA, Normal LV
function
148 98 28 22 162 56 1.2 299.2 T2DM// CAD/ LRI 1
26 Govindasamy 61 1 150 88 3 3 13 130 185 168 278 9.2 Qs in V1 - V4 Hypokinesia of antero
basal segment, Ef 45%
146 98 28 20 160 55 1.2 312 T2DM/ CAD/ OLD IWMI/
VIVAX MALARIA
1
27 Natarajan 61 1 136 88 3 1 14 130 185 156 266 7.8 Qs II, III, avF mild hypokinesia of
inferobasl wall, EF
50%
130 80 30 20 146 55 1.1 310 T2DM/CAD/OLD
IWMI/COPD EXACERBATION
1
28 Valluvan 62 1 142 86 1 1 14 103 158 136 246 8.7 NSR, WNL No RWMA, Normal LV
function
149 86 45 18 132 36 0.9 298.2 T2DM/CAD/COPD
EXACERBATION
1
29 Gunalan 55 64 1 152 90 1 1 15 162 217 162 272 9.2 NSR, WNL No RWMA, Normal LV
function
120 60 40 20 100 36 1 312 T2DM/CAD/ old PT/ COPD
EXACERBATION
1
30 sundaram 64 1 154 92 1 1 15 120 175 156 266 7.7 NSR, no specific ST-T
changes
No RWMA, Normal LV
function
138 88 30 20 90 50 1 334.2 T2DM/CAD/ LEFT LL
PNUEMONIA
1
31 Karpagam 64 1 140 82 1 1 15 120 175 142 252 8.8 NSR. WNL No RWMA, Normal LV
function
130 82 32 16 80 32 0.8 282.2 T2DM/AD/ bronchial asthma
exacerbation
1
32 Karnan 64 1 160 88 1 3 15 112 167 182 292 8.7 NSR, T wave↓ I, avL No RWMA, Normal LV
function
146 98 28 20 156 50 1.1 282.2 T2DM/CAD/ acute febrile
illness
1
33 Lalitha 64 1 140 86 1 1 16 108 163 136 246 8.4 NSR. WNL No RWMA, Normal LV
function
124 68 38 18 98 38 1 274.4 T2DM/CAD/ acute febrile
illness for evaluation
1
34 Chellatha 65 2 162 92 3 4 16 142 197 199 309 9.1 Qs II, III, avF Hypokinesia of
inferobasal segment,
EF 45%
152 102 28 22 162 51 1.3 332.2 T2DM/ OLD IWMI/ fever for
evaluation
1
35 Krishnan 65 2 140 80 1 1 16 102 157 132 242 6.4 NSR. WNL No RWMA, Normal LV
function
123 66 38 19 120 36 1 286 T2DM/CAD/ ADD WITH
MILD DEHYDRATION
1
36 Maragadam 66 2 154 92 1 3 17 130 185 182 292 9.1 NSR, T↓ v5, v6 No RWMA, Normal LV
function
121 72 29 20 135 55 1.1 332 T2DM/CAD/  COPD
EXACERABATION
2
37 Elavarasi 66 2 142 86 1 1 17 120 175 156 266 8.9 NSR. WNL No RWMA, Normal LV
function
126 68 38 20 110 42 0.9 270 T2DM/CAD/  COPD
EXACERABATION
2
38 Muthusamy 66 2 154 88 1 1 17 122 177 155 265 8.4 T ↓ V2 - V4 No RWMA, Normal LV
function
112 60 32 20 134 50 1 311.2 T2DM/CAD/ acute febrile
illness for evaluation
2
39 Kannagi 68 2 140 82 1 1 18 106 161 142 252 9 NSR. WNL No RWMA, Normal LV
function
130 76 38 16 102 50 0.9 283.2 T2DM/CAD/ MALARIAL
FEVER
2
40 Natarajan 69 2 148 88 1 1 18 130 185 184 294 9.4 NSR. WNL No RWMA, Normal LV
function
266 92 32 142 20 38 1.1 323.2 T2DM/CAD/FEVER WITH
ARTHRALGIA
2
41 Krishnamoorthy 67 2 130 88 1 1 18 120 175 146 256 8.5 Qs V1-V5 Hypokinesia of AW
septum, EF 45%
126 76 30 20 126 35 0.8 312 SHT/CAD/ OLD AWMI/LVF 2
42 Krishnaraj 70 2 150 100 1 1 19 132 187 193 303 7.2 T ↓ avL, V5,V6 No RWMA, conc. LVH 152 102 25 22 110 40 1 273.2 SHT/UA/ LATERAL WALL
ISCHEMIA
2
43 Mani 70 2 140 86 1 3 19 140 195 200 310 8.8 NSR. WNL No RWMA, Normal LV
function
132 84 28 20 130 42 0.9 297 SHT/UA 2
44 Krishnaveni 71 2 110 84 1 1 21 132 187 155 265 8.4 Low voltage complex with
PPRW
Global hypokinesia of
LV, EF 35%
132 84 28 20 132 45 1.1 325.2 T2DM/SHT/CAD/ISCHEMIC
DCMP/CCF
2
45 Muthukannan 73 2 156 96 1 3 21 146 201 206 316 9.5 ST↓v2-v5 Grade 1 DD 119 67 34 18 98 36 1.1 298 T2DM/SHT/CAD/RECURRENT
ANGINA
2
46 Rajappa 74 2 136 94 1 1 21 133 188 156 266 9.1 NSR,T↓L1,Avl No RWMA, Normal LV
function
151 102 26 23 145 42 1 326 T2DM/CAD/DYSLIPIDEMIA/S
HT/LW ISCHEMIA
2
47 Lalitha 75 2 138 94 1 1 22 123 178 156 266 8.9 WNL Normal LV function 146 88 38 20 124 40 0.8 286 T2DM/CAD/ENTERIC FEVER 2
48 Santhanam 76 2 124 78 1 1 23 106 161 137 247 8.6 WNL Normal LV function 140 76 46 18 97 37 0.9 256 T2DM/CAD/GERD 2
49 Henry 77 2 156 94 3 3 24 133 188 187 297 9.1 QS L1,Avl,v5,v6 Hypokinesia of
Laterobasal segment,
EF 43%
117 67 30 20 138 56 1.1 334 T2DM/CAD/UA 2
50 Rasiya bebum 87 2 100 70 1 3 24 155 210 224 334 9.8 QS L2,L3 & aVF Hypokinesia of
Inferior segment of
LV, EF 28%
132 82 32 18 122 34 1 390.4 T2DM/CAD/OLD
IWMI/DCMP/CCF
2
